Does KRMD pay a dividend and is it safe?

KORU Medical Systems Inc. (KRMD) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / KRMD / dividends

LUNG (38) SKYA (43) STIM (28) APYX (21) ⌘ Pro Terminal →

KORU Medical Systems Inc. (KRMD) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.05 +2.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.06

KORU Medical Systems Inc. (KRMD) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $138.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KRMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, KORU Medical Systems Inc. (NASDAQ: KRMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $3.05 (+2.01% 1D, market cap $138.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, KRMD ranks #443 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KRMD compare to LUNG and SKYA in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), KRMD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of -28.7%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $129.1M) and SKYA (SkyAI Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M). Among the 5-stock peer group, KRMD leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KRMD?

▼

Per KRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000704440), KORU Medical Systems Inc. generated $41.1M in revenue (+22.2% YoY), -$2.6M in net income, and $462.4K in free cash flow against $28.2M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.06 (+0.17%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRMD)Realized 20D OHLCV Swing Band: ±9.7%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY KRMD SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (39% of score)

Altman Z-Score 8.05 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 1.1% FCF Margin ($462.4K FCF) & 62.3% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.00+1.3% Next Q

Q2 (-2Q)

Grade E$3.04+4.3% Next Q

Q3 (-1Q)

Grade E$3.17-3.8% Next Q

Current

Grade D-$3.05-7.2% Hist 90D α

Trajectory: E (33) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KRMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KRMD currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.13) and Max Pain ($3.20) forces dealer call-delta covering toward $6.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (12.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $33,350

Est. Year-10 Shareholder Yield: $200/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.3K

Yr 1

$12.7K

Yr 2

$14.4K

Yr 3

$16.2K

Yr 4

$18.3K

Yr 5

$20.6K

Yr 6

$23.2K

Yr 7

$26.2K

Yr 8

$29.6K

Yr 9

$33.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KRMD)

✓Walkthrough of KRMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.56%▼ DESCENDING CHANNEL

2026-11-03O $3.23H $3.23L $2.99C $3.05VOL 165.2K

RES: $3.30SUP: $2.65SMA50: $3.13SMA200: $3.99

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KRMD Butterfly Map → + Track KRMD →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KRMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KRMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRMD)

Health Care Rank #443 of 1015 ⚔️ LUNG vs KRMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KRMD vs. LUNG, SKYA, STIM, APYX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, KORU Medical Systems Inc. (KRMD) ranks #443 by composite RQD confidence (41/100, grade D-) and #613 by equity capitalization ($138.1M). Within this direct 5-issuer industry benchmark cohort, KRMD leads on earnings valuation at N/A trailing P/E, while KRMD leads on capital efficiency and profitability with -28.7% ROIC and 62.3% gross margin. SKYA currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with KRMD at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KRMD ACTIVE KORU Medical Systems Inc.	D-	41/100	—	62.3%	-28.7%	+2.01%	$138.1M	Benchmark Subject
LUNG Pulmonx Corporation	D-	38/100	—	74.2%	-35.0%	-14.14%	$129.1M	/lung-vs-krmd →
SKYA SkyAI Inc.	D-	43/100	—	-30.0%	-35.0%	-1.35%	$128.4M	/skya-vs-krmd →
STIM Neuronetics Inc.	E	28/100	—	48.5%	-35.0%	-8.44%	$171.4M	/stim-vs-krmd →
APYX Apyx Medical Corporation	E	21/100	—	62.5%	-28.9%	0.00%	$109.5M	/apyx-vs-krmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000704440 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), KORU Medical Systems Inc. (KRMD) reported GAAP revenue of $41.1M (+22.2% vs. FY2024 revenue of $33.6M , and +44.2% cumulative change since FY2023) , GAAP net income of -$2.6M, operating cash flow of $462.4K, and free cash flow of $462.4K (+244.6% YoY). On the balance sheet, KRMD closed FY2025 with $28.2M in total assets against $0 in total debt (Altman Z-Score: 8.05, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$41.1M	-$2.6M	$462.4K	$462.4K	$28.2M	—
FY2024 (FY)	2024-12-31	$33.6M	-$6.1M	-$319.7K	-$319.7K	$27.2M	—
FY2023 (FY)	2023-12-31	$28.5M	-$13.7M	-$4.9M	-$4.9M	—	—

3. KRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does KRMD compare to LUNG and SKYA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for KRMD?

Where is KRMD trading relative to its 50-day, 200-day, and 52-week technical levels?

KRMD last traded at $3.05 (+2.01% on volume of 221,701 shares), positioning the stock -2.56% below its 50-day simple moving average ($3.13) and -23.56% below its 200-day simple moving average ($3.99). Across its 52-week range of $2.86 to $6.61, KRMD sits at the 5.1% percentile with a 14-day RSI of 44.5 (NEUTRAL RANGE) and an implied next-earnings move of ±9.7% ($2.75 to $3.35).

Direct Sub-Reports: KRMD RQD Cockpit KRMD 12M Forecast KRMD Earnings & Move KRMD Dividends & DRIP KRMD Insiders & 13F KRMD Whale Options KRMD Profit Sankey KRMD News & Why

ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

KRMD — KORU Medical Systems Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

KORU Medical Systems Inc. (KRMD) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.05 (+2.01% 1D, market capitalization $138.1M).

Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of -28.7%, gross margin of 62.3%, operating margin of -7.2%, and free cash flow yield of 0.31%.
Whale 13F & Options Flow (4/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (5/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 8.05, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

KORU Medical Systems Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry (per the SEC profile). The profile does not describe its products, customers, or revenue model in source data. Market capitalization is $0.1B. Revenue of $41.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), KORU Medical Systems Inc. (KRMD) reported $41.1M in annual revenue (up from $33.6M in FY2024, +22.2% YoY) and -$2.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($28.5M revenue, -$13.7M net income) through FY2025, KRMD scaled operating cash flow to $462.4K and free cash flow to $462.4K, backed by $28.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 41/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 0.31% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $2.86 – $6.61 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -7.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The sector and industry classification (Health Care; Medical/Dental Instruments) is the only contextual link provided. A prospective investor should note that the absence of mapped dependencies means second-order bottlenecks cannot be identified from the source data.

Key Question #1: Can KRMD sustain or expand its -7.2% operating margin and -28.7% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $41.1M and free cash flow of $462.4K, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is KRMD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KRMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for KORU Medical Systems Inc. (KRMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KRMD Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

KORU Medical Systems to Report Third Quarter 2026 Financial Results on November 10, 2026

Yahoo Finance report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

KORU Medical Systems, Inc. Estimates – NASDAQ:KRMD

TradingView report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 1d ago

Form 4 KORU Medical Systems Inc: Shahriar Matin (Director) For: 1 October

Investing.com UK report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

KORU Medical Systems (KRMD) Holds Steady at $3.02 as Shares Edge Higher - Volatility Smile

https://www.siam.in/ report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 1d ago

Form 4 KORU Medical Systems Inc For: 8 October By Investing.com

Investing.com Canada report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Precision Optics Corporation (POCI) Stock Price, News & Analysis

Stock Titan report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KRMD Bull vs. Bear Conversation Board — What's Your Call at $3.05?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KRMD 🐻 33% BEARISH CONVICTION

BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $3.47 (+16.1%)

📌 Pinned Debate

The balance sheet scores strongest in the rating (Altman Z 8.05, Piotroski F 7/9, Debt/Equity 0.5) and revenue grew from $28.5M to $41.

Picked up a starter position in KRMD in my $100K Virtual Cash book at $2.99. The balance sheet scores strongest in the rating (Altman Z 8.05, Piotroski F 7/9, Debt/Equity 0.5) and revenue grew from $28.5M to $41.1M while the net loss narrowed from -$13.7M to -$2.6M.. Trading inside a $2.86–$6.61 52-week range with 0.31% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@MultipleCompression Shorting a 4/20 institutional whale-flow stock at $2.99 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $2.36 (-21.1%)

Spot @ $2.99

ROIC of -28.7%, an FCF yield of 0.31%, and a beta of 1.0 with a macro regime fit score of 5/20 leave the stock without cash-generation

Here is the bear case nobody on the bull side wants to address on KRMD: ROIC of -28.7%, an FCF yield of 0.31%, and a beta of 1.0 with a macro regime fit score of 5/20 leave the stock without cash-generation or defensive support, and the rating carries a distribution warning.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.